Immune Pharmaceuticals (IMNP) Receives Daily News Sentiment Rating of 0.10

Headlines about Immune Pharmaceuticals (NASDAQ:IMNP) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Immune Pharmaceuticals earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.267816005066 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Immune Pharmaceuticals (IMNP) opened at 1.08 on Friday. The stock’s market capitalization is $11.42 million. The firm has a 50 day moving average price of $1.42 and a 200 day moving average price of $1.79. Immune Pharmaceuticals has a 52 week low of $0.12 and a 52 week high of $5.02.

ILLEGAL ACTIVITY WARNING: “Immune Pharmaceuticals (IMNP) Receives Daily News Sentiment Rating of 0.10” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at

About Immune Pharmaceuticals

Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.

Insider Buying and Selling by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)

Receive News & Ratings for Immune Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Leave a Reply